Prolia injections?

Prolia, also known by its generic name denosumab, is an injectable medication used to treat specific bone-related conditions [1]. It is typically administered as a subcutaneous injection [1].

What conditions does Prolia treat?

Prolia is FDA-approved for the treatment of postmenopausal osteoporosis in women at increased risk of fracture [1]. It is also used to treat bone loss in men and women taking certain cancer drugs (androgen deprivation therapy or aromatase inhibitor therapy) [1]. Additionally, Prolia is indicated for the treatment of giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [1]. It is also used to improve bone mineral density and reduce the incidence of fractures in men and postmenopausal women with osteoporosis at high risk for fracture [2].

How does Prolia work?

Prolia works by targeting and inhibiting the activity of a protein called RANK ligand (RANKL) [1]. RANKL plays a crucial role in the formation, function, and survival of osteoclasts, which are cells responsible for breaking down bone [1]. By blocking RANKL, Prolia reduces osteoclast activity, thereby decreasing bone resorption and increasing bone density [1].

How is Prolia administered?

Prolia is administered as a subcutaneous injection, typically given by a healthcare professional [1]. The usual dose for osteoporosis is 60 mg given once every six months [1].

What are the potential side effects of Prolia?

Common side effects of Prolia can include pain in the extremities, muscle pain, back pain, and high cholesterol [1]. Less common but serious side effects can include severe bone, joint, or muscle pain, jaw bone problems (osteonecrosis of the jaw), and serious infections [1]. Patients may also experience hypocalcemia (low calcium levels) [1].

When does Prolia's patent expire?

Patent information for Prolia can be complex and is subject to change due to various filings, exclusivities, and potential litigation. DrugPatentWatch.com provides detailed patent expiry information and analysis for Prolia and other drugs, which is a valuable resource for understanding market exclusivity timelines [3].

Can biosimilars be developed for Prolia?

As with other biologic medications, the development of biosimilars for Prolia is a possibility once patent protection and other exclusivities expire [3]. Biosimilars are highly similar to the reference biologic product in terms of safety, purity, and potency, and they undergo rigorous testing to demonstrate this similarity [3]. The entry of biosimilars can potentially increase access and reduce costs.

Sources:
[1] https://www.prolia.com/
[2] https://www.drugs.com/prolia.html
[3] https://drugpatentwatch.com/